ArticleMuscle & nerve2026
Azathioprine Toxicity in Patients With Myasthenia Gravis: A Single Center Experience.
Article in Muscle & nerve, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
INTRODUCTION/
aimsAzathioprine (AZA) is a first-line immunosuppressive agent for myasthenia gravis (MG), yet most toxicity data for AZA are from gastrointestinal literature. The aim of the current study is to add a large MG patient cohort with a comprehensive evaluation of the adverse event profile of AZA and associations between patient demographics and drug reactions.
methodsPatients were identified from the Duke Electronic Medical Record using EPIC's SlicerDicer tool. INCLUSION CRITERIA: MG diagnosis confirmed by antibody/electrodiagnostic testing, evaluation by a Duke neuromuscular physician, and AZA use between January 1, 2014 and January 7, 2023. Drug reaction was defined as an abnormal lab result or symptomatic side effect after AZA initiation.
resultsAmong 145 patients, 96 (66%) developed a drug reaction; 63 (43.5%) required AZA dose reduction or discontinuation, and 23 (16%) had symptomatic side effects. Most reactions improved with dose reduction or observation. Leukopenia, macrocytosis, and hepatotoxicity were the most frequent. For every additional comorbidity, the odds of drug reaction increased by 30% (OR 1.3; 95% CI 1.12-1.51; p < 0.001). Flu-like reactions occurred in 10% of patients. Cancer incidence (4.1%) was rare and there were no cases of Pneumocystis jirovecii pneumonia despite rare use of trimethoprim-sulfamethoxazole prophylaxis. DISCUSSION: AZA drug reactions were common but infrequently severe or symptomatic. Higher comorbidity burden predicted drug reactions. Most laboratory abnormalities resolved without AZA discontinuation, supporting individualized monitoring and dose adjustment rather than automatic cessation. Lower doses should be considered for balancing efficacy with dose-dependent drug reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.